TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD Other Situations 8-K Filing 2023 - Entry into a Material Definitive Agreement Teva Pharmaceuticals has entered into a deferred prosecution agreement with the U.S. Department of Justice to settle price-fixing charges, requiring them to pay a $225 million fine over five years and divest one generic product.Get access to all SEC 8-K filings of the TEVA PHARMACEUTICAL INDUSTRIES LTD